Primary biliary cholangitis 5

Summary

Primary biliary cholangitis 5 (MONDO:0013637) is a disease. A subtype of primary biliary cholangitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary biliary cholangitis 5
Mondo ID	MONDO:0013637
OMIM	614221
DOID	DOID:0070362
UMLS	C3280202
MedGen	481832
GARD	0015777
Is cancer (heuristic)	no

Also known as: biliary cirrhosis, primary, 5 · PBC5

Disease family

This is a subtype of primary biliary cholangitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › primary biliary cholangitis › primary biliary cholangitis 5

Related subtypes (4): primary biliary cholangitis 1, primary biliary cholangitis 2, primary biliary cholangitis 3, primary biliary cholangitis 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.